Fewer than 10% of individuals who could benefit from obesity jabs like Wegovy have access to them, warns the World Health Organization as it issues its inaugural recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging broader and more equitable availability to GLP-1 medication.
Based on projections, more than two billion will be obese by 2030 without intervention.
"Our latest guidance recognises that excess weight is a lifelong illness that can be treated with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are significant obstacles to universal availability to the jabs that can assist patients in reducing significant body mass, notes the body.
GLP-1 Therapy Shortage
Even under the current best projected case, the production of such drugs could only cover approximately 100 million people – fewer than 10% of the global need, per the WHO.
The recommendation urges countries and companies to widen availability, by measures including patent sharing.
Exclusive production rights on the active ingredient – the primary ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.
How Obesity Injections Work
GLP-1 drugs replicate a natural hormone to delay gastric emptying, reduce hunger and increase the sense of being full so people eat less.
Individuals typically see weight reduction in the initial weeks of starting on the once-weekly jabs.
Studies suggests patients may see weight return a year later of halting the medication, as their usual hunger come back.
To be carrying excess weight elevates your likelihood for developing health problems, including diabetes, heart disease, stroke, and specific malignancies.
Excess weight affects individuals in all nations and was associated with millions of fatalities worldwide in 2024, per the health agency.
